The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Improving cure rates in NHL and future treatments
Paolo Caimi, MD, University Hospitals Cleveland Medical Center & Case Western Reserve University, Cleveland, OH, talks on the improving cure rates of non-Hodgkin lymphoma (NHL) and discussess where he sees the field moving in the future. Dr Caimi also outlines novel therapies being developed for NHL treatment, including loncastuximab tesirine, polatuzumab, and selinexor, and comments on the need to target therapies more accurately. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
